Morgan Stanley
EPZM

Morgan Stanley’s Epizyme, Inc EPZM Stock Holding History

Morgan Stanley’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-836,955
Closed -$1.23M – 8176
2022
Q2 		$1.23M Buy
836,955
+18,564
+2% +$13.6K ﹤0.01% 4889
2022
Q1 		$941K Buy
818,391
+30,031
+4% +$49K ﹤0.01% 5038
2021
Q4 		$1.97M Sell
788,360
-1,920,113
-71% -$7.54M ﹤0.01% 4598
2021
Q3 		$13.9M Buy
2,708,473
+684,721
+34% +$4.16M ﹤0.01% 2519
2021
Q2 		$16.8M Buy
2,023,752
+144,711
+8% +$1.22M ﹤0.01% 2348
2021
Q1 		$16.4M Buy
1,879,041
+9,795
+0.5% +$101K ﹤0.01% 2133
2020
Q4 		$20.3M Buy
1,869,246
+419,919
+29% +$5.18M ﹤0.01% 1798
2020
Q3 		$17.3M Buy
1,449,327
+762,758
+111% +$10.2M ﹤0.01% 1586
2020
Q2 		$11M Buy
686,569
+594,874
+649% +$10.4M ﹤0.01% 1882
2020
Q1 		$1.42M Sell
91,695
-294,942
-76% -$6.33M ﹤0.01% 3660
2019
Q4 		$9.51M Buy
386,637
+97,935
+34% +$1.45M ﹤0.01% 2484
2019
Q3 		$2.98M Sell
288,702
-18,206
-6% -$230K ﹤0.01% 3423
2019
Q2 		$3.85M Sell
306,908
-35,954
-10% -$463K ﹤0.01% 3190
2019
Q1 		$4.25M Sell
342,862
-133,165
-28% -$1.49M ﹤0.01% 2865
2018
Q4 		$2.93M Sell
476,027
-49,667
-9% -$379K ﹤0.01% 3454
2018
Q3 		$5.57M Sell
525,694
-64,990
-11% -$742K ﹤0.01% 3067
2018
Q2 		$8M Buy
590,684
+416,939
+240% +$6.49M ﹤0.01% 2626
2018
Q1 		$3.08M Buy
173,745
+63,379
+57% +$1.07M ﹤0.01% 3575
2017
Q4 		$1.39M Buy
110,366
+13,521
+14% +$197K ﹤0.01% 4329
2017
Q3 		$1.84M Buy
96,845
+46,333
+92% +$707K ﹤0.01% 3960
2017
Q2 		$763K Sell
50,512
-32,001
-39% -$484K ﹤0.01% 4565
2017
Q1 		$1.42M Sell
82,513
-44,358
-35% -$591K ﹤0.01% 4111
2016
Q4 		$1.53M Sell
126,871
-129,196
-50% -$1.35M ﹤0.01% 4146
2016
Q3 		$2.52M Sell
256,067
-14,149
-5% -$129K ﹤0.01% 3301
2016
Q2 		$2.77M Sell
270,216
-16,467
-6% -$184K ﹤0.01% 3147
2016
Q1 		$3.47M Sell
286,683
-6,052
-2% -$61.2K ﹤0.01% 2857
2015
Q4 		$4.69M Sell
292,735
-17,055
-6% -$253K ﹤0.01% 2722
2015
Q3 		$3.98M Buy
309,790
+291,683
+1,611% +$5.89M ﹤0.01% 2855
2015
Q2 		$434K Buy
18,107
+106
+0.6% +$2.04K ﹤0.01% 4817
2015
Q1 		$338K Sell
18,001
-35,946
-67% -$742K ﹤0.01% 4910
2014
Q4 		$1.02M Sell
53,947
-4,556
-8% -$106K ﹤0.01% 4133
2014
Q3 		$1.59M Buy
58,503
+40,711
+229% +$1.27M ﹤0.01% 3624
2014
Q2 		$554K Buy
17,792
+2,204
+14% +$51.9K ﹤0.01% 4505
2014
Q1 		$355K Sell
15,588
-1,214
-7% -$36.8K ﹤0.01% 4785
2013
Q4 		$349K Buy
16,802
+4,854
+41% +$141K ﹤0.01% 4717
2013
Q3 		$478K Sell
11,948
-62,257
-84% -$2.11M ﹤0.01% 4364
2013
Q2 		$2.09M Buy
+74,205
New +$1.91M ﹤0.01% 3118

Other funds holding EPZM

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Morgan Stanley's EPZM Position: Q3 2022 in Review

Morgan Stanley sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 836,955 shares — an estimated $1.23M sold.

Morgan Stanley first reported a position in EPZM in Q2 2013 and held it in 37 quarters. The position peaked at $20.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

  • Morgan Stanley reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
  • Morgan Stanley sold 836,955 Epizyme, Inc shares in Q3 2022, an estimated $1.23M.
  • Morgan Stanley first reported a position in Epizyme, Inc in Q2 2013 and held it in 37 quarters.
  • Morgan Stanley's Epizyme, Inc position peaked at $20.3M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.